«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2024年04期

页码:

568-574

栏目:

论著

出版日期:

2024-08-25

文章信息/Info

Title:

Efficacy and safety of inhaled ambroxol hydrochloride solution in treating chronic obstructive pulmonary disease patients with phlegm

作者:

马锦芳¹; 何正光²; 郑劲平³

510120 广州,广州医科大学附属第一医院呼吸与危重症医学科¹、国家呼吸系统疾病临床医学研究中心³
629099 四川,遂宁市第三人民医院呼吸与危重症医学科²

Author(s):

Ma Jinfang¹;  He Zhengguang²;  Zheng Jinping³.

¹Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; ²Department of Respiratory and Critical Care Medicine, The Third People's Hospital of Suining, Suining 629099, China; ³National Clinical Research Center for Respiratory Diseases, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China

关键词:

肺疾病; 慢性阻塞性;  盐酸氨溴索;  雾化吸入;  黏痰症;  生活质量

Keywords:

Chronic obstructive pulmonary disease;  Ambroxol hydrochloride;  Nebulization inhalation;  Phlegm;  Quality of life

分类号:

R563

DOI:

10.3877/cma.j.issn.1674-6902.2024.04.012

摘要:

目的 分析雾化吸入盐酸氨溴索(ambroxol hydrochloride)溶液治疗慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)黏痰症患者的临床疗效和安全性。方法 选择2021年 5月至2022年4月来自32家医院收治的COPD患者316例为对象。COPD患者给予吸氧、消炎、舒张支气管等常规治疗基础上,伴有黏痰症状和咳痰困难的COPD患者采用雾化吸入盐酸氨溴索溶液,每次3 ml(2 ml︰15 mg),一日2次,持续治疗7天。比较治疗前后患者呼吸道黏痰性状、咳痰难易程度、痰量和咳嗽、生活质量的变化,同时进行敏感性分析和按临床是否属于COPD急性加重期进行亚组分析。结果 共纳入符合筛选标准的COPD患者316例。与治疗前相比,治疗结束时患者痰液性状、咳痰难易程度、痰液量、咳嗽症状和痰液黏稠度均有明显改善,评分分别下降1.64分(95%CI:-1.73,-1.56)、1.41分(95%CI:-1.50,-1.33)、1.10分(95%CI:-1.19,-1.01)、1.22分(95%CI:-1.30,-1.13)和1.73分(95%CI:-1.83,-1.64),生活质量评分则增加0.06分(95%CI:0.05,0.07),差异具有统计学意义(P<0.05)。治疗时间越长临床综合总疗效高(P<0.05),治疗后第1天、第3天、第5天和治疗结束时临床总疗效的例数分别为125例(39.56%)、215例(68.04%)、265例(83.86%)和285例(90.19%)。亚组分析和敏感性分析结果与总体结果一致。不良反应发生率为4.75%,未发生严重不良反应。结论 雾化吸入盐酸氨溴索溶液能有效改善COPD患者黏痰症,安全性及耐受性好。

Abstract:

Objective This study aims to analyse the efficacy and safety of nebulization inhalation of ambroxol hydrochloride solution in the treatment of chronic obstructive pulmonary disease(COPD)patients with phlegm. Methods A total of 316 COPD patients meeting the screening criteria were enrolled in 32 hospitals from May 2021 to April 2022, conducted to administer nebulized inhalation of ambroxol hydrochloride solution 3 ml(2 ml︰15 mg)twice a day for up to seven days to adult COPD patients with symptoms of phlegm and difficulty in expectoration. Changes in respiratory sputum characteristics, difficulty of expectoration, sputum volume, cough, and quality of life of patients before and after treatment were compared, and sensitivity analysis and subgroup analysis were also performed based on whether they belong to an acute exacerbation stage in clinical practice. Results A total of 316 COPD patients meeting the screening criteria were enrolled. Compared with the condition prior to treatment, the patient showed significant improvement in sputum characteristics, difficulty in coughing up sputum, sputum volume, cough symptoms, and sputum viscosity at the completion of treatment. The scores decreased by 1.64(95%CI: -1.73, -1.56), 1.41(95%CI: -1.50, -1.33), 1.10(95%CI: -1.19, -1.01), 1.22(95%CI: -1.30, -1.13), and 1.73(95%CI: -1.83, -1.64)respectively. Additionally, the quality of life score increased by 0.06 points(95%CI: 0.05, 0.07). These differences were statistically significant(P<0.05). Furthermore, a longer treatment duration correlated with a higher overall clinical efficacy rate(P<0.05). The number of cases exhibiting overall clinical efficacy on the first, third, fifth day post-treatment, and at the completion of treatment were 125(39.56%), 215(68.04%), 265(83.86%), and 285(90.19%), respectively. The results of subgroup analysis and sensitivity analysis were consistent with the overall results. The incidence of adverse reactions was 4.75%, and there were no serious adverse reactions. Conclusion Nebulization inhalation of ambroxol hydrochloride solution can effectively improve phlegm in COPD patients and is safe and well-tolerated.

参考文献/References:

1 Bonnevie T, Elkins M. Chronic obstructive pulmonary disease[J]. J Physiother, 2020, 66(1): 3-4.
2 Ferrera MC, Labaki WW, Han MK. Advances in chronic obstructive pulmonary disease[J]. Annu Rev Med, 2021, 72: 119-134.
3 Macleod M, Papi A, Contoli M, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact[J]. Respirology, 2021, 26(6): 532-551.
4 周淑华, 徐秀萍, 毛芝芳, 等. 左氧氟沙星与氨溴索联合治疗对慢性阻塞性肺疾病合并肺部感染老年患者的疗效研究[J]. 中华医院感染学杂志, 2018, 28(6): 848-851.
5 苏 兵. 盐酸氨溴索雾化吸入治疗慢性阻塞性肺疾病急性加重期的疗效观察[J]. 医学理论与实践, 2015, 28(8): 1032-1033.
6 吕宇基, 叶品钊, 卢国圣. 盐酸氨溴索联合雾化吸入对老年慢性阻塞性肺疾病合并肺部感染的治疗效果[J]. 慢性病学杂志, 2020, 21(03): 371-374.
7 中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205.
8 殷凯生, 张劲松, 孙丽华, 等. 国产氨溴索片祛痰的疗效及安全性[J]. 中国新药与临床杂志, 2000, 19(002): 99-101.
9 陈雪融, 杜鑫淼, 刘春涛, 等. 国产注射用盐酸氨溴索治疗下呼吸道感染的多中心随机对照临床试验[J]. 中国循证医学杂志, 2007, 7(7): 483-486.
10 施 毅, 肖永营, 苏 欣, 等. 注射用盐酸氨溴索粘痰溶解与祛痰作用的多中心临床随机对照研究[J]. 临床内科杂志, 2005, 22(9): 598-600.
11 张绍塘, 陈 伦, 叶 健. 多索茶碱联合盐酸氨溴索对老年稳定期慢阻肺患者血清IL-33/sST2轴表达的影响[J]. 中国临床药理学杂志, 2022, 38(4): 291-295.
12 吕青兰. 盐酸氨溴索对急性期慢性阻塞性肺疾病患者血清CRP、白细胞介素17及白细胞介素18的影响[J]. 重庆医学, 2015, 44(8): 1151-1152.
13 潘 珍, 黎嘉文. 大剂量盐酸氨溴索对肺部的保护作用的Meta分析[J]. 中国药房, 2014, 25(32): 3041-3045.
14 Li Z. The effect of adjuvant therapy with ambroxol hydrochloride in elderly chronic obstructive pulmonary disease patients[J]. Am J Transl Res, 2021, 13(8): 9285-9295.
15 王 侃, 赵白云, 缪晓青, 等. 盐酸氨溴索辅助治疗新生儿感染性肺炎的疗效与相关药理机制研究[J]. 中华医院感染学杂志, 2019, 29(11): 1713-1716.
16 刘虎军, 高莉萍. 不同剂量盐酸氨溴索注射液治疗老年慢性阻塞性肺疾病急性加重期患者对炎性细胞因子的影响[J]. 昆明医科大学学报, 2017, 38(9): 119-123.
17 陈丽展, 吴 朔, 张 艳, 等. 盐酸氨溴索对烟所致慢性阻塞性肺疾病大鼠肺组织细胞凋亡和血管重塑的作用机制研究[J]. 现代生物医学进展, 2020, 20(15): 2817-2823.
18 Deretic V, Timmins GS. Enhancement of lung levels of antibiotics by ambroxol and bromhexine[J]. Expert Opin Drug Metab Toxicol, 2019, 15(3): 213-218.
19 Wang Y, Li X, Wang D, et al. In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii[J]. Lett Appl Microbiol, 2020, 70(3): 189-195.
20 Calefi PHS, De Azevedo Queiroz I, Alcalde M, et al. Comparison of the Physicochemical Properties, Antimicrobial Action, and Cytotoxicity of Ambroxol Hydrochloride, N-acetylcysteine, and Calcium Hydroxide Pastes[J]. Eur Endod J, 2022, 7(3): 217-222.
21 Li X, Wu X, Gao Y, et al. Apoptosis-linked antifungal effect of ambroxol hydrochloride by cystolic calcium concentration disturbance in resistant Candida albicans[J]. Sci China Life Sci, 2019, 62(12): 1601-1604.
22 何 洪, 何 凯. 氨溴索对慢性阻塞性肺疾病急性加重期的疗效及肺功能的影响[J]. 中国医药科学, 2011, 1(7): 24-25.
23 林 红. 氨溴索注射液对COPD患者临床疗效及其对肺功能的影响[J]. 实用药物与临床, 2012, 15(9): 567-568.
24 侯思捷, 叶泉英, 赖 昕, 等. 氨溴索联合纳洛酮对COPD呼吸衰竭合并肺部真菌感染患者的治疗效果[J]. 中华医院感染学杂志, 2022, 32(18): 2757-2761.
25 Cazan D, Klimek L, Sperl A, et al. Safety of ambroxol in the treatment of airway diseases in adult patients[J]. Expert Opin Drug Saf, 2018, 17(12): 1211-1224.
26 鞠俊强, 朱正太, 李 华, 等. 不同剂量盐酸氨溴索在老年慢性阻塞性肺疾病急性加重期的应用比较[J]. 泰州职业技术学院学报, 2017, 17(5): 43-45.
27 林金鱼, 陈亚红. 不同剂量盐酸氨溴索治疗慢性阻塞性肺疾病急性加重期老年患者的疗效比较[J]. 中国医药, 2014, 8(8): 1120-1124.
28 刘 静. 不同剂量盐酸氨溴索注射液在老年慢性阻塞性肺疾病合并呼吸衰竭患者治疗中的应用比较[J]. 中国药物与临床, 2021, 21(5): 808-810.
29 Zhou ZB, Yang LL, Hu C, et al. The combination of astragalus injection and ambroxol hydrochloride in the adjuvant treatment of COPD: a systematic review and meta-analysis[J]. Sci Rep, 2023, 13(1): 22077.
30 Li M, Bao JL, Yang L. The clinical efficacy of combining ambroxol hydrochloride with antibiotics for the treatment of chronic bronchitis[J]. Altern Ther Health Med, 2024: AT10614.
31 Zhang XQ, Zhang XH, Gu JH, et al. The efficacy of nebulized budesonide and ambroxol hydrochloride in treating pediatric community-acquired pneumonia and their impact on clinical characteristics and inflammatory markers[J]. J Health Popul Nutr, 2024, 43(1): 132.

备注/Memo

备注/Memo:

通信作者: 郑劲平, Email:jpzhenggy@163.com

常用功能

更新日期/Last Update: 2024-08-25